Effects of Abcg2 C421a and Abcg2 G34a Genetic Polymorphisms on Clinical Outcome and Response to Imatinib Mesylate, in Iranian Chronic Myeloid Leukemia Patients Publisher



Nouri N^{1, 2} ; Mehrzad V^{3, 4} ; Khalaj Z² ; Zaker E^{1, 2} ; Zare F^{5, 6} ; Abbasi E^{7, 8} ; Khosravi M² ; Kalantar SM^{1, 9} ; Salehi M^{2, 7, 8} Show Affiliations
Source: Egyptian Journal of Medical Human Genetics Published:2023

Abstract

Background: Chronic myeloid leukemia (CML) is a multifactorial clonal myeloid neoplasm that mainly arises from the Philadelphia chromosome. Even though imatinib mesylate (IM) is considered the gold standard for first-line treatment, a number of CML patients have shown IM resistance that can be influenced by many factors, including pharmacogenetic variability. The present study examined whether two common single nucleotide polymorphisms (SNPs) of ABCG2 (G34A and C421A) contribute to IM resistance and/or good responses. Material and methods: A total of 72 CML patients were genotyped with high-resolution melting (HRM) and restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). We also determined the cytogenetic and hematological response, as evaluable factors for measuring response to imatinib. Results: In the current study, we explored the relationship between the different variants of ABCG2 G34A and C421A and clinical response to imatinib among CML patients. There were no statistically significant differences between genotypes of C421A and G34A and allele frequencies among the resistant and responder groups, with response to IM (P > 0.05). Also, we found no statistically significant association between genotypes and cytogenetic and hematological responses. Conclusion: This is the first study to investigate the association between genotypes of the G34A and C421A SNPs and the outcome of IM treatment in Iranian population. As a whole, genotyping of these SNPs is unhelpful in predicting IM response in CML patients. © 2023, The Author(s).